Tscan Therapeutics is trading 3.9% up at $0.79 today after announcing the first patient dosing of its lead T-cell therapy, TSC-101, in the pivotal Phase 3 ALLOHA-2 trial for AML and MDS. - The trial evaluates the efficacy of TSC-101 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). - This late-stage clinical milestone reflects investor enthusiasm.